Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with ROS1-positive non-small cell lung cancer

C-ros oncogene 1 receptor tyrosine kinase (ROS1) rearrangement forms a novel molecular subgroup of non-small cell lung cancer (NSCLC). The present study explored the clinicopathological features and clinical efficacy of crizotinib in patients with ROS1-positive NSCLC. A retrospective analysis of 2,6...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncol Lett
Autores principales: Zhu, You-Cai, Zhang, Xin-Gen, Lin, Xue-Ping, Wang, Wen-Xian, Li, Xiao-Feng, Wu, Li-Xin, Chen, Hua-Fei, Xu, Chun-Wei, Du, Kai-Qi
Formato: Artigo
Lenguaje:Inglês
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6396181/
https://ncbi.nlm.nih.gov/pubmed/30867785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2019.9949
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares